Provided by Tiger Trade Technology Pte. Ltd.

Scholar Rock Holding Corp

53.14
-2.2700-4.10%
Volume:2.27M
Turnover:122.33M
Market Cap:6.47B
PE:-15.81
High:56.90
Open:56.51
Low:52.60
Close:55.41
52wk High:61.76
52wk Low:27.07
Shares:121.79M
Float Shares:107.73M
Volume Ratio:2.74
T/O Rate:2.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3601
EPS(LYR):-3.4845
ROE:-167.77%
ROA:-58.82%
PB:25.50
PE(LYR):-15.25

Loading ...

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid AI Pullback

MT Newswires Live
·
Yesterday

Scholar Rock Says Its First Muscle-Targeted SMA Therapy Will Cost About $310,000 Annually

Reuters
·
Yesterday

Wedbush Sticks to Their Buy Rating for Scholar Rock Holding (SRRK)

TIPRANKS
·
Yesterday

Scholar Rock Holding Price Target Maintained with a $64.00/Share by Wedbush

Dow Jones
·
Yesterday

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Yesterday

Scholar Rock Exec Says Its First Drug to Target Muscle Loss in Spinal Mus­Cu­Lar at­Ro­Phy Has a Wholesale Acquisition Cost of $11,659 for a Single Use Vial - Conf.call

THOMSON REUTERS
·
Yesterday

Scholar Rock Exec Says Co Expects the Annual Net Cost in the U.S. for a Typical Patient to be Approximately $310,000

THOMSON REUTERS
·
Yesterday

Scholar Rock price target raised to $84 from $76 at BMO Capital

TIPRANKS
·
Yesterday

Top Premarket Gainers

MT Newswires Live
·
Yesterday

Truist Raises Price Target on Scholar Rock Holding to $76 From $55, Keeps Buy Rating

MT Newswires Live
·
Yesterday

Scholar Rock Shares up 11.6% Premarket After FDA Nod for First Muscle-Targeted Drug for Type of Genetic Disease

THOMSON REUTERS
·
Yesterday

Scholar Rock Holding Corporation : Citigroup Raises Target Price to $74 from $60

THOMSON REUTERS
·
Yesterday

Scholar Rock Gets FDA Approval for Spinal Muscular Atrophy Treatment in Children, Adults; Shares Up Pre-Bell

MT Newswires Live
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Scholar Rock Holding (SRRK) and Danaher (DHR)

TIPRANKS
·
Yesterday

Scholar Rock announces FDA approval of isembyld

TIPRANKS
·
Sep 12

FDA Approves Scholar Rock’s Isembyld for Spinal Muscular Atrophy Patients Aged 2 and Older on SMN2 Therapy

Reuters
·
Sep 12

Scholar Rock Holding Corporation - Isembyld U.S. Commercial Launch Underway; Product Available to Ship in Coming Days

THOMSON REUTERS
·
Sep 12

Scholar Rock Announces FDA Approval of Isembyld™ (Apitegromab-Mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (Sma)

THOMSON REUTERS
·
Sep 12

US FDA Approves Scholar Rock's Muscle Weakness Drug

Reuters
·
Sep 12

US FDA - Approves Isembyld for Spinal Muscular Atrophy in Patients Aged 2 Years and Older

THOMSON REUTERS
·
Sep 12